Shanghai Fosun Pharmaceutical (Group) Co Ltd (600196)-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8013237)
◆英語タイトル:Shanghai Fosun Pharmaceutical (Group) Co Ltd (600196) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013237
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:94
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥32,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥64,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥96,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Shanghai Fosun Pharmaceutical (Group) Co Ltd (Fosun Pharma), a subsidiary of Shanghai Fosun High Technology (Group) Co Ltd is a drug company that offers pharmaceutical products, medical diagnostic products and medical device products. The company’s pharmaceutical products include metabolism and digestive system, cardiovascular system, blood system, central nervous system drugs, anti-infection, anti-tumor, vaccine and raw material and intermediates. It provides medical diagnostic products such as real time PCR detector, human papillomavirus genotyping kit, HBV quantitative reagent, and biofosun microorganism identification and susceptibility analysis system. The company’s research and development unit concentrates on therapeutic areas of metabolism and digestive system, blood system, cardiovascular system and central nervous system. Fosun Pharma is headquartered in Shanghai, China.

Shanghai Fosun Pharmaceutical (Group) Co Ltd (600196) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Medical Devices Deals, 2011 to YTD 2017 12
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 13
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deal Details 18
Asset Purchase 18
Shanghai Fosun Pharma Plans to Acquire Medicine Products from Sandoz for USD18 Million 18
Venture Financing 19
Ambrx Raises USD45 Million in Venture Financing 19
Saladax Biomedical Raises US$23 Million In Series D Venture Financing 21
Private Equity 23
KKR Receives Government Approval To Acquire 35% Stake In Gland Pharma For USD200 Million 23
Partnerships 24
CMIC Enters and Fosun Pharma Enter into Joint Venture Agreement 24
Kite Pharma Forms Joint Venture with Fosun Pharma 25
Breckenridge Pharma Enters into Marketing Agreement with Gland Pharma 26
Dr. Reddy’s Labs Enters into Co-Marketing Agreement with Gland Pharma 27
Nature’s Sunshine Products Forms Joint Venture with Fosun Pharma 28
Miacom Diagnostics Enters into Co-Marketing Agreement with Fosun Diagnostics 29
Maxigen Biotech Enters into Agreement with Shanghai Fosun Pharma 30
Atrium Innovations Forms Joint Venture With Fosun Industrial 31
Biotest Enters Into Distribution Agreement With Wanbang Biopharma For Human Serum Albumin 32
Shanghai Fosun Enters Into Joint Venture With Dalian Wanchun To Develop Oncology Treatments 33
Shanghai Fosun Pharma Enters Into Co-Development Agreement With Shanghai Institute of Materia Medica To Develop Cancer Drug 34
Litha Pharma Partners with Gland Pharma 35
Shanghai Fosun Enters Into Joint Venture Agreement With Lonza Group 36
Licensing Agreements 37
Shanghai Fosun Pharma Enters into Licensing Agreement with Palatin Technologies 37
Athenex to Enter into Licensing Agreement with Gland Pharma 38
Athenex to Enter into Licensing Agreement with Gland Pharma 39
Shanghai Fosun Pharma Enters into Licensing Agreement with LegoChem Biosciences 40
TB Alliance Enters Into Licensing Agreement With Fosun Pharma 41
Shenzhen Salubris Pharma Enters Into Licensing Agreement With Shanghai Fosun Pharma For Diabetes Drug 42
Equity Offering 43
Shanghai Fosun Pharma to Raise USD298.3 Million in Private Placement of Shares 43
Chindex to Raise USD38.2 Million in Private Placement of Shares 45
Phagelux Raises Funds through Private Placement 46
Shanghai Fosun Pharma Decreases Size of Private Placement of Shares for USD376 Million 47
Shanghai Fosun Pharma Raises USD940 Million in Private Placement of Shares 48
Shanghai Fosun Pharma to Raise Funds through Private Placement of Shares 49
Amerigen Pharma to Raise USD35 Million in Private Placement of Shares 50
Nature’s Sunshine Raises USD46 Million in Private Placement of Shares 51
Shanghai Fosun Pharma Prices Private Placement Of Shares For US$229.6 Million 53
Debt Offering 54
Shanghai Fosun Pharma Plans to Raise up to USD1 Billion in Private Placement of Bonds 54
Shanghai Fosun Pharma Plans to Raise USD928 Million in Private Placement of Bonds 55
Shanghai Fosun Pharma to Raise USD459 Million in First Tranche Public Offering of Bonds Due 2021 56
Shanghai Fosun Pharma Raises USD65.3 Million in First Tranche of Private Placement of 3.95% Notes Due 2018 57
Shanghai Fosun Pharma Announces Public Offering Of Corporate Bonds To Raise Up To US$469.8 Million 58
Asset Transactions 59
Sinopharm Plans to Acquire Pharmacy Business from Shanghai Fosun Pharma 59
Acquisition 60
Shanghai Fosun Pharma to Acquire 69.3% Stake in Henlix Biotech for USD98 Million 60
Shanghai Fosun Pharma Acquires 74% Stake in Gland Pharma for USD1.1 Billion 61
Wuhan Mayinglong Pharma Sells 51% Stakes in Hubei Tianxiaming Pharma for USD2.9 Million 63
Shanghai Fosun Pharma to Acquire 2.6% Stake in Jinzhou Austrian Hong Pharma for USD26 Million 64
Shanghai Fosun Pharma, HOPU Investments, CEL Healthcare Fund and WuXi PharmaTech to Acquire Ambrx 65
Shanghai Fosun Pharma Plans to Acquire 65% Stake in Suzhou Erye for USD137 Million 67
Sinopharm Plans to Acquire Three Pharmacies from Shanghai Fosun Pharma for USD67 Million 68
Shanghai Fosun Pharma To Acquire Additional 28% Stake In Jinzhou Aohong Pharma For Up To US$304 Million 69
Winteam Pharma Completes Acquisition Of Tongjitang Chinese Medicines From Hanmax And Fosun International For US$426.4 Million 70
Fosun Pharma Acquires 50% Stake In Guangzhou Nanyang Tumour Hospital 72
Wanbang Biopharma Acquires 51% Stake In Zaozhuang Sainuokang 73
Shanghai Fosun Pharma Completes Acquisition Of 77.78% Stake In Hunan Dongting Pharma For US$93 Million 74
Shanghai No. 1 Pharmacy Plans To Acquire 50% Stake In Shanghai-Based Chain Pharmacy Company 75
Shanghai Fosun Pharma Completes Acquisition Of 55% Stake In Zhongwu Hospital 76
Fosun Pharma Acquires 11% Stake In Shenzhen Belter For US$7 Million 77
Fosun Pharma Acquires Additional Stake In Beijing Golden Elephant Pharmacy 78
Shanghai Fosun Pharma To Acquire 70% Stake In Jinzhou Ahon For US$213 Million 79
Shanghai Fosun To Sell 68.6% Stake In Zhejiang Fosun To Sinopharm Group 80
Shanghai Fosun Pharma Acquires 75% Stake In Dalian Aleph Bio-medical 81
Shanghai Fosun Pharmaceutical (Group) Co Ltd – Key Competitors 82
Shanghai Fosun Pharmaceutical (Group) Co Ltd – Key Employees 83
Shanghai Fosun Pharmaceutical (Group) Co Ltd – Locations And Subsidiaries 85
Head Office 85
Other Locations & Subsidiaries 85
Joint Venture 85
Recent Developments 87
Corporate Communications 87
Sep 05, 2017: Fosun Pharmas Subsidiary Sisram, the World’s Leading Energy-Based Medical Aesthetic Treatment Systems Provider, to be Listed as the First Israeli Company on the Main Board of SEHK 87
Jun 29, 2016: Shanghai Fosun Pharmaceutical (Group) Announces Resignation Of Non-Executive Director 90
Jun 07, 2016: Shanghai Fosun Pharmaceutical Announces Management Changes, Names New President and CEO 91
Mar 02, 2016: Resignation Of Non-Executive Director: Shanghai Fosun Pharmaceutical 93
Appendix 94
Methodology 94
About GlobalData 94
Contact Us 94
Disclaimer 94

List of Tables
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Deals By Therapy Area, 2011 to YTD 2017 10
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Medical Devices Deals, 2011 to YTD 2017 12
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 13
Shanghai Fosun Pharma Plans to Acquire Medicine Products from Sandoz for USD18 Million 18
Ambrx Raises USD45 Million in Venture Financing 19
Saladax Biomedical Raises US$23 Million In Series D Venture Financing 21
KKR Receives Government Approval To Acquire 35% Stake In Gland Pharma For USD200 Million 23
CMIC Enters and Fosun Pharma Enter into Joint Venture Agreement 24
Kite Pharma Forms Joint Venture with Fosun Pharma 25
Breckenridge Pharma Enters into Marketing Agreement with Gland Pharma 26
Dr. Reddy’s Labs Enters into Co-Marketing Agreement with Gland Pharma 27
Nature's Sunshine Products Forms Joint Venture with Fosun Pharma 28
Miacom Diagnostics Enters into Co-Marketing Agreement with Fosun Diagnostics 29
Maxigen Biotech Enters into Agreement with Shanghai Fosun Pharma 30
Atrium Innovations Forms Joint Venture With Fosun Industrial 31
Biotest Enters Into Distribution Agreement With Wanbang Biopharma For Human Serum Albumin 32
Shanghai Fosun Enters Into Joint Venture With Dalian Wanchun To Develop Oncology Treatments 33
Shanghai Fosun Pharma Enters Into Co-Development Agreement With Shanghai Institute of Materia Medica To Develop Cancer Drug 34
Litha Pharma Partners with Gland Pharma 35
Shanghai Fosun Enters Into Joint Venture Agreement With Lonza Group 36
Shanghai Fosun Pharma Enters into Licensing Agreement with Palatin Technologies 37
Athenex to Enter into Licensing Agreement with Gland Pharma 38
Athenex to Enter into Licensing Agreement with Gland Pharma 39
Shanghai Fosun Pharma Enters into Licensing Agreement with LegoChem Biosciences 40
TB Alliance Enters Into Licensing Agreement With Fosun Pharma 41
Shenzhen Salubris Pharma Enters Into Licensing Agreement With Shanghai Fosun Pharma For Diabetes Drug 42
Shanghai Fosun Pharma to Raise USD298.3 Million in Private Placement of Shares 43
Chindex to Raise USD38.2 Million in Private Placement of Shares 45
Phagelux Raises Funds through Private Placement 46
Shanghai Fosun Pharma Decreases Size of Private Placement of Shares for USD376 Million 47
Shanghai Fosun Pharma Raises USD940 Million in Private Placement of Shares 48
Shanghai Fosun Pharma to Raise Funds through Private Placement of Shares 49
Amerigen Pharma to Raise USD35 Million in Private Placement of Shares 50
Nature's Sunshine Raises USD46 Million in Private Placement of Shares 51
Shanghai Fosun Pharma Prices Private Placement Of Shares For US$229.6 Million 53
Shanghai Fosun Pharma Plans to Raise up to USD1 Billion in Private Placement of Bonds 54
Shanghai Fosun Pharma Plans to Raise USD928 Million in Private Placement of Bonds 55
Shanghai Fosun Pharma to Raise USD459 Million in First Tranche Public Offering of Bonds Due 2021 56
Shanghai Fosun Pharma Raises USD65.3 Million in First Tranche of Private Placement of 3.95% Notes Due 2018 57
Shanghai Fosun Pharma Announces Public Offering Of Corporate Bonds To Raise Up To US$469.8 Million 58
Sinopharm Plans to Acquire Pharmacy Business from Shanghai Fosun Pharma 59
Shanghai Fosun Pharma to Acquire 69.3% Stake in Henlix Biotech for USD98 Million 60
Shanghai Fosun Pharma Acquires 74% Stake in Gland Pharma for USD1.1 Billion 61
Wuhan Mayinglong Pharma Sells 51% Stakes in Hubei Tianxiaming Pharma for USD2.9 Million 63
Shanghai Fosun Pharma to Acquire 2.6% Stake in Jinzhou Austrian Hong Pharma for USD26 Million 64
Shanghai Fosun Pharma, HOPU Investments, CEL Healthcare Fund and WuXi PharmaTech to Acquire Ambrx 65
Shanghai Fosun Pharma Plans to Acquire 65% Stake in Suzhou Erye for USD137 Million 67
Sinopharm Plans to Acquire Three Pharmacies from Shanghai Fosun Pharma for USD67 Million 68
Shanghai Fosun Pharma To Acquire Additional 28% Stake In Jinzhou Aohong Pharma For Up To US$304 Million 69
Winteam Pharma Completes Acquisition Of Tongjitang Chinese Medicines From Hanmax And Fosun International For US$426.4 Million 70
Fosun Pharma Acquires 50% Stake In Guangzhou Nanyang Tumour Hospital 72
Wanbang Biopharma Acquires 51% Stake In Zaozhuang Sainuokang 73
Shanghai Fosun Pharma Completes Acquisition Of 77.78% Stake In Hunan Dongting Pharma For US$93 Million 74
Shanghai No. 1 Pharmacy Plans To Acquire 50% Stake In Shanghai-Based Chain Pharmacy Company 75
Shanghai Fosun Pharma Completes Acquisition Of 55% Stake In Zhongwu Hospital 76
Fosun Pharma Acquires 11% Stake In Shenzhen Belter For US$7 Million 77
Fosun Pharma Acquires Additional Stake In Beijing Golden Elephant Pharmacy 78
Shanghai Fosun Pharma To Acquire 70% Stake In Jinzhou Ahon For US$213 Million 79
Shanghai Fosun To Sell 68.6% Stake In Zhejiang Fosun To Sinopharm Group 80
Shanghai Fosun Pharma Acquires 75% Stake In Dalian Aleph Bio-medical 81
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Key Competitors 82
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Key Employees 83
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Subsidiaries 85
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Joint Venture 85

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Shanghai Fosun Pharmaceutical (Group) Co Ltd (600196)-製薬・医療分野:企業M&A・提携分析(Shanghai Fosun Pharmaceutical (Group) Co Ltd (600196) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆